Cogent Biosciences (COGT)
(Delayed Data from NSDQ)
$11.36 USD
-0.69 (-5.73%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $11.45 +0.09 (0.79%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
COGT 11.36 -0.69(-5.73%)
Will COGT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for COGT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COGT
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success
Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade
COGT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Cogent Biosciences (COGT) Stock a Solid Choice Right Now?
Is Cogent Biosciences (COGT) Outperforming Other Medical Stocks This Year?
Other News for COGT
Cogent Biosciences reports Q2 results
Cogent Biosciences Inc Reports Q2 2025 Net Loss of $73.5 Million Amid Increased R&D Expenses
Cogent Biosciences Inc (COGT) Reports Positive Clinical Trial Results and Strong Financial ...
COGT: Bezuclastinib Shows Promising Results in Key Clinical Trial
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial ...